Spots Global Cancer Trial Database for antitumor activity
Every month we try and update this database with for antitumor activity cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects | NCT01012258 | Squamous Cell C... | Cetuximab + con... | 18 Years - | Merck KGaA, Darmstadt, Germany | |
An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations | NCT02192697 | Non-small Cell ... | ASP8273 | 20 Years - | Astellas Pharma Inc | |
Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia | NCT02316197 | Advanced Solid ... Chronic Lymphoc... | MSC2490484A (M3... | 18 Years - | Merck KGaA, Darmstadt, Germany | |
Phase I Study of TAS-106 in Combo With Carboplatin | NCT00752011 | Cancer Solid Tumors | TAS-106 Carboplatin | 18 Years - | M.D. Anderson Cancer Center | |
Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects | NCT01012258 | Squamous Cell C... | Cetuximab + con... | 18 Years - | Merck KGaA, Darmstadt, Germany | |
Phase I Study of TAS-106 in Combo With Carboplatin | NCT00752011 | Cancer Solid Tumors | TAS-106 Carboplatin | 18 Years - | M.D. Anderson Cancer Center | |
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors | NCT01182883 | Brain Stem Neop... Glioma Pinealoma | IMC-A12 Temsirolimus | 1 Year - 21 Years | National Institutes of Health Clinical Center (CC) | |
MEDI5752 in Japanese Patients With Advanced Solid Tumors. | NCT05685472 | Advanced Solid ... | MEDI5752 | 18 Years - 120 Years | AstraZeneca |